Optimal cardiometabolic health and risk of heart failure in type 2 diabetes: an analysis from the Look AHEAD trial

被引:6
|
作者
Patel, Kershaw V. [1 ]
Khan, Muhammad Shahzeb [2 ]
Segar, Matthew W. [3 ]
Bahnson, Judy L. [4 ]
Garcia, Katelyn R. [4 ]
Clark, Jeanne M. [5 ]
Balasubramanyam, Ashok [6 ]
Bertoni, Alain G. [7 ]
Vaduganathan, Muthiah [8 ,9 ]
Farkouh, Michael E. [10 ,11 ]
Januzzi, James L., Jr. [12 ]
Verma, Subodh [13 ]
Espeland, Mark [4 ]
Pandey, Ambarish [14 ]
机构
[1] Houston Methodist DeBakey Heart & Vasc Ctr, Dept Cardiol, Houston, TX USA
[2] Duke Univ, Sch Med, Div Cardiol, Durham, NC USA
[3] Texas Heart Inst, Dept Cardiol, Houston, TX 77025 USA
[4] Wake Forest Univ, Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA
[5] Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Sch Med, Div Gen Internal Med, Dept Med,Dept Epidemiol, Baltimore, MD USA
[6] Baylor Coll Med, Dept Internal Med, Sect Endocrinol Diabet & Metab, Houston, TX 77030 USA
[7] Wake Forest Univ Sch Med, Div Publ Hlth Sci, Winston Salem, NC USA
[8] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA
[9] Harvard Med Sch, Boston, MA 02115 USA
[10] Univ Toronto, Peter Munk Cardiac Ctr, Toronto, ON, Canada
[11] Univ Toronto, Heart & Stroke Richard Lewar Ctr, Toronto, ON, Canada
[12] Harvard Med Sch, Massachusetts Gen Hosp, Baim Inst Clin Res, Boston, MA 02115 USA
[13] Univ Toronto, St Michaels Hosp, Div Cardiac Surg, Toronto, ON, Canada
[14] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Div Cardiol, Dallas, TX USA
基金
美国国家卫生研究院;
关键词
Cardiometabolic health; Heart failure; Type 2 diabetes mellitus; LIFE-STYLE INTERVENTION; CARDIOVASCULAR-DISEASE; OBESE ADULTS; PREVENTION; OVERWEIGHT;
D O I
10.1002/ejhf.2723
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To evaluate the contribution of baseline and longitudinal changes in cardiometabolic health (CMH) towards heart failure (HF) risk among adults with type 2 diabetes (T2D). Methods and results Participants of the Look AHEAD trial with T2D and without prevalent HF were included. Adjusted Cox models were used to create a CMH score incorporating target levels of parameters weighted based on relative risk for HF. The associations of baseline and changes in the CMH score with risk of overall HF, HF with preserved (HFpEF) and reduced ejection fraction (HFrEF) were assessed using Cox models. Among the 5080 participants, 257 incident HF events occurred over 12.4 years of follow-up. The CMH score included 2 points each for target levels of waist circumference, glomerular filtration rate, urine albumin-to-creatinine ratio, and 1 point each for blood pressure and glycated haemoglobin at target. High baseline CMH score (6-8) was significantly associated with lower overall HF risk (adjusted hazard ratio [HR], ref = low score (0-3): 0.31, 95% confidence interval [CI] 0.21-0.47) with similar associations observed for HFpEF and HFrEF. Improvement in CMH was significantly associated with lower risk of overall HF (adjusted HR per 1-unit increase in score at 4 years: 0.80, 95% CI 0.70-0.91). In the ACCORD validation cohort, the baseline CMH score performed well for predicting HF risk with adequate discrimination (C-index 0.70), calibration (chi-square 5.53, p = 0.70), and risk stratification (adjusted HR [high (6-8) vs. low score (0-3)]: 0.35, 95% CI 0.26-0.46). In the Look AHEAD subgroup with available biomarker data, incorporating N-terminal pro-B-type natriuretic peptide to the baseline CMH score improved model discrimination (C-index 0.79) and risk stratification (adjusted HR [high (8-10) vs. low score (0-4)]: 0.18, 95% CI 0.09-0.35). Conclusions Achieving target levels of more CMH parameters at baseline and sustained improvements were associated with lower HF risk in T2D. [GRAPHICS] .
引用
收藏
页码:2037 / 2047
页数:11
相关论文
共 50 条
  • [31] Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
    Komajda, Michel
    McMurray, John J. V.
    Beck-Nielsen, Henning
    Gomis, Ramon
    Hanefeld, Markolf
    Pocock, Stuart J.
    Curtis, Paula S.
    Jones, Nigel P.
    Home, Philip D.
    EUROPEAN HEART JOURNAL, 2010, 31 (07) : 824 - 831
  • [32] Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD
    Ferreira, Joao Pedro
    Vasques-Novoa, Francisco
    Ferrao, Diana
    Saraiva, Francisca
    Falcao-Pires, Ines
    Neves, Joao Sergio
    Sharma, Abhinav
    Rossignol, Patrick
    Zannad, Faiez
    Leite-Moreira, Adelino
    DIABETES CARE, 2022, 45 (07) : 1584 - 1591
  • [33] Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials
    Giugliano, Dario
    Maiorino, Maria Ida
    Longo, Miriam
    Bellastella, Giuseppe
    Chiodini, Paolo
    Esposito, Katherine
    ENDOCRINE, 2019, 65 (01) : 15 - 24
  • [34] Effect of improved fitness beyond weight loss on cardiovascular risk factors in individuals with type 2 diabetes in the Look AHEAD study
    Gibbs, Bethany Barone
    Brancati, Frederick L.
    Chen, Haiying
    Coday, Mace
    Jakicic, John M.
    Lewis, Cora E.
    Stewart, Kerry J.
    Clark, Jeanne M.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2014, 21 (05) : 608 - 617
  • [35] Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials
    Dario Giugliano
    Maria Ida Maiorino
    Miriam Longo
    Giuseppe Bellastella
    Paolo Chiodini
    Katherine Esposito
    Endocrine, 2019, 65 : 15 - 24
  • [36] Physical Activity and Weight Loss Among Adults With Type 2 Diabetes and Overweight or Obesity A Post Hoc Analysis of the Look AHEAD Trial
    Huang, Zihao
    Zhuang, Xiaodong
    Huang, Rihua
    Liu, Menghui
    Xu, Xinghao
    Fan, Ziyan
    Dai, Rongling
    Li, Hansheng
    Xiong, Zhenyu
    Guo, Yue
    Liang, Qi
    Liao, Xinxue
    JAMA NETWORK OPEN, 2024, 7 (02) : E240219
  • [37] The Look AHEAD Trial: Bone Loss at 4-Year Follow-up in Type 2 Diabetes
    Lipkin, Edward W.
    Schwartz, Ann V.
    Anderson, Andrea M.
    Davis, Cralen
    Johnson, Karen C.
    Gregg, Edward W.
    Bray, George A.
    Berkowitz, Robert
    Peters, Anne L.
    Hodges, Amelia
    Lewis, Cora
    Kahn, Steven E.
    DIABETES CARE, 2014, 37 (10) : 2822 - 2829
  • [38] Effect of a lifestyle intervention on change in cardiorespiratory fitness in adults with type 2 diabetes: results from the Look AHEAD Study
    Jakicic, J. M.
    Jaramillo, S. A.
    Balasubramanyam, A.
    Bancroft, B.
    Curtis, J. M.
    Mathews, A.
    Pereira, M.
    Regensteiner, J. G.
    Ribisl, P. M.
    INTERNATIONAL JOURNAL OF OBESITY, 2009, 33 (03) : 305 - 316
  • [39] Impact of intensive lifestyle intervention on preference-based quality of life in type 2 diabetes: Results from the Look AHEAD trial
    Zhang, Ping
    Hire, Don
    Espeland, Mark A.
    Knowler, William C.
    Thomas, Sheikilya
    Tsai, Adam G.
    Glick, Henry A.
    OBESITY, 2016, 24 (04) : 856 - 864
  • [40] Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes
    Standl, Eberhard
    Schnell, Oliver
    McGuire, Darren K.
    CIRCULATION RESEARCH, 2016, 118 (11) : 1830 - 1843